Showing 601 - 620 results of 39,013 for search '(( 5 ((non decrease) OR (nn decrease)) ) OR ( 50 ((we decrease) OR (a decrease)) ))', query time: 1.04s Refine Results
  1. 601

    Supramolecular DNA Photonic Hydrogels for On-Demand Control of Coloration with High Spatial and Temporal Resolution by Yixiao Dong (2174902)

    Published 2021
    “…We solve this problem by creating a DNA hydrogel system that shows a 50 000-fold decrease in modulus upon heating by ∼10 °C. …”
  2. 602
  3. 603
  4. 604

    Synthesis and Characterization of New Organometallic Benzo[<i>b</i>]thiophene Derivatives with Potential Antitumor Properties by André P. Ferreira (2348185)

    Published 2009
    “…The benzo[<i>b</i>]thiophene derivative raloxifene is a selective estrogen receptor modulator (SERM) that has been found to decrease breast cancer risk in postmenopausal women compared to placebo. …”
  5. 605
  6. 606
  7. 607
  8. 608

    Image_1_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.TIF by Hilde L. Orrem (5740313)

    Published 2018
    “…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”
  9. 609

    Image_2_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.TIF by Hilde L. Orrem (5740313)

    Published 2018
    “…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”
  10. 610

    Table_1_IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.DOCX by Hilde L. Orrem (5740313)

    Published 2018
    “…</p><p>Results: Our main findings were (i) Tocilizumab decreased C5aR1 and C5aR2 mRNA expression significantly (p < 0.001) and substantially (>50%) at day 2 and 3, whereas C3aR expression was unaffected. …”
  11. 611
  12. 612
  13. 613
  14. 614
  15. 615
  16. 616
  17. 617
  18. 618
  19. 619
  20. 620

    Sensitivity analysis of 50:50 model. by Rachael Miller Neilan (10678614)

    Published 2021
    “…<p>A sensitivity analysis was conducted on the 50:50 model with constant 120 pA current to determine the sensitivity of pain output to select model parameters before injury (t = 10), during injury (t = 105), and after injury (t = 240). …”